Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:32:48.411Z.
Calculation as of: 2026-10-06T22:32:48.411Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d71c6897c98d436948f76d79272a6a7ae3c560285f8867db41996dc6a6301e16
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Oncolytics Biotech Inc.
Market Cap
$60.02M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Oncolytics Biotech Inc. (ONCY) | $60.02M | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | N/A |
| Talphera, Inc. (TLPH)vs › | $57.61M | N/A |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
